Prof. Dr. Philipp Beckhove, Scientific Director at the LIT, explains in an interview with the Science Blog of the University of Regensburg what influence Sakaguchi’s discovery of “peripheral” immune tolerance, in particular regulatory T cells (Tregs), had on immunology, how the collaboration with Shimon Sakaguchi came about, and how the new findings are paving the way for future immunotherapies.
Researchers at the University Hospital Regensburg and the Leibniz Institute for Immunotherapy (LIT) are embarking on an innovative project, ESOSTEM155, aimed at transforming T cell-based cancer therapies. This initiative has been awarded a two-year grant of 460,000 EUR from the National Strategy for Gene and Cell-based Therapies (GCT) funding program.
More than 150 leading scientists from around the world discussed latest developments in immunological research and the treatment of diseases such as cancer, autoimmune diseases, and chronic inflammation at the International Symposium of the Leibniz Institute for Immunotherapy June 26th – 27th, 2024 in Regensburg.
We would be delighted to have you with us in Regensburg and participate in our LIT Symposium 2022. Title: Smart Cells: Synthetic Immunology / Synthetic Biology
We would be delighted to have you with us in Regensburg and participate in our public lectures in 2019/20.
We would be delighted to have you with us in Regensburg and participate in our LIT Symposium 2019. Title: Synthetic immunology and environment-adapted redirection of T cells
We would be delighted to have you with us in Regensburg and to participate in our public Lectures in 2018/19.
